Government Intensifies Surveillance as GLP-1 Generics Flood Indian Market
NEW DELHI: The Indian government has significantly escalated its oversight of GLP-1 receptor agonist drugs, prompted by a sharp decline in prices and the widespread availability of their generic versions. This intensified scrutiny aims to curb misuse, with authorities inspecting 49 businesses, issuing notices, and releasing a detailed advisory highlighting the critical risks of unsupervised consumption.
To uphold ethical pharmaceutical practices, the Drug Controller General of India (DCGI) has launched a nationwide campaign to bolster surveillance against the unauthorized sale and promotion of these potent medications. In India, GLP-1 drugs are exclusively prescribed by specialized medical professionals, including endocrinologists, internal medicine specialists, and cardiologists, underscoring their controlled use.
Officials have voiced growing concerns over the increasing on-demand availability of these drugs through various channels, including retail pharmacies, online platforms, wholesalers, and wellness clinics. Inspections conducted across the country have uncovered a range of violations, from improper prescriptions to misleading marketing tactics, necessitating immediate regulatory intervention.
The comprehensive advisory specifically directs manufacturers to cease all advertisements that promote the non-prescription use of GLP-1 drugs. Authorities have issued stern warnings of severe consequences for non-compliance, which may include the cancellation of licenses, substantial fines, and legal action. While instrumental in treating type 2 diabetes and obesity, GLP-1 medications carry serious health risks if misused, with potential side effects ranging from vomiting to severe complications such as pancreatitis, kidney injury, and bowel obstruction.
About the Author
